VivoSeq
Other

Paralysis

25

Pipeline Programs↗

4

Active Trials↗

16

Companies Involved↗

Paralysis is an emerging landscape with 25 programs across 16 companies. The most active players are Emergent BioSolutions, Bristol-Myers Squibb, Revance Therapeutics, Inc.. 10 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

18/100

Completion Rate

75/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Emergent BioSolutions logo

Emergent BioSolutions

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1R

Revance Therapeutics, Inc.

1 program

Phase 1V

Validus Pharmaceuticals

1 program

Phase 2T

Triax

1 program

Phase 3F

Fresenius Kabi Oncology Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

29 of 30 classified programs — the dominant modality here.

3%ALL OTHERSCell therapy13%

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 100% of 33 pipeline programs.

Analysis

Trial Status

26

clinical trials

Completed15 · 58%
Terminated5 · 19%
Unknown status2 · 8%
Active, not recruiting2 · 8%
Recruiting1 · 4%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

26 trials

Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block
Recruiting·—·N/A·NCT04209504·60 enrolled
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
Active, not recruiting·NNationwide Children's Hospital·Phase 4·NCT03769844·120 enrolled
Transformation of Paralysis to Stepping
Active, not recruiting·UUniversity of Louisville·Phase 1·NCT04105114·15 enrolled
Comparative Evaluation of Diaphragmatic Function Following Interscalene, Anterior Suprascapular, and Costoclavicular Nerve Blocks in Shoulder Surgery
Not yet recruiting·MMenoufia University·Approved·NCT07671352·75 enrolled
Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye
Completed·IInstituto de Oftalmología Fundación Conde de Valenciana·Phase 1·NCT02403219·20 enrolled
The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia
Completed·RRadboud University Medical Center·N/A·NCT01374711·18 enrolled
Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis
Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·N/A·NCT01503840·20 enrolled
The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy
Completed·MMayo Clinic·Phase 1·NCT01495962·46 enrolled
Comparison of Neuromuscular Blockade's Monitoring and Clinical Assessment During Cisatracurium Paralysis in Critically Ill Patients
Completed·PPoitiers University Hospital·Phase 3·NCT03198637·50 enrolled
Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle
Completed·Emergent BioSolutions logoEmergent BioSolutions·Phase 1·NCT00636519·36 enrolled
Ultrasound-guided Interscalene Block:3mL Ropi Provide Similar Analgesia to 5mL and Less Diaphragmatic Paralysis
Completed·—·N/A·NCT04317235·60 enrolled
The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia
Completed·RRadboud University Medical Center·N/A·NCT02922673·30 enrolled
Incidence Of Hemidiaphragmatic Paralysis After Usg Guided Low Dose Interscalene Brachial Plexus Block
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT03081728·56 enrolled
The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis
Completed·RRadboud University Medical Center·Phase 3·NCT01649921·4 enrolled
Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy
Completed·WWest Virginia University·Phase 4·NCT03111121·79 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)